A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : IVIG / intravenous IgG

[Related PubMed/MEDLINE]
Total Number of Papers: 59
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   IVIG  (>> Co-occurring Abbreviation)
Long Form:   intravenous IgG
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Aggregation and Particle Formation During Pumping of an Antibody Formulation Are Controlled by Electrostatic Interactions Between Pump Surfaces and Protein Molecules. ---
2020 Study of usefulness of low-dose IgG for patients with septic disseminated intravascular coagulation. DIC
2019 Bumbling, Stumbling, Fumbling: Weakness, Steppage Gait, and Facial Droop in a 3-Year-Old Male. CSF, GBS, Ig
2019 Managing cost of care and healthcare utilization in patients using immunoglobulin agents. Ig, SCIG
2019 Reconstitution of IgG Subclasses following Immunoglobulin Therapy in Adult Primary Hypogammaglobulinemia. fSCIG, Ig, SCIG
2018 Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment. CDR3, Ig, KD
2018 Long-Term Efficacy and Safety of Hizentra in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. AEs, IgG, PID, SCIG
2017 FcgammaRIIb expression on B cells is associated with treatment efficacy for acute rejection after kidney transplantation. AR, BUN, FcgammaR, mAb, SCr
2017 Low rate of infectious complications following immunoadsorption therapy without regular substitution of intravenous immunoglobulins. CRP, IA, Ig
10  2017 Neuroinvasive St. Louis Encephalitis Virus Infection in Solid Organ Transplant Recipients. IFN, SLE, SLEV, WNV
11  2016 Improved outcomes on subcutaneous IgG in patients with humoral immunodeficiency and co-morbid bowel disease. CVID, SCIG
12  2016 Intravenous and subcutaneous immunoglobulin G replacement therapy. IgG, SCIG
13  2016 Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency. CI
14  2015 Anti-A and anti-B hemagglutinin depletion during Cohn purification process of 5% immunoglobulin. DAT, FC, IgG, RBCs
15  2015 Intravenous IgG (IVIG) and subcutaneous IgG (SCIG) preparations have comparable inhibitory effect on T cell activation, which is not dependent on IgG sialylation, monocytes or B cells. SCIG
16  2015 Potentiation of cytokine-induced proliferation of human Natural Killer cells by intravenous immunoglobulin G. ---
17  2014 Clinical characteristics of hemophagocytic lymphohistiocytosis following Kawasaki disease: differentiation from recurrent Kawasaki disease. HLH-KD
18  2014 Development, manufacturing and characterization of a highly purified, liquid immunoglobulin g preparation from human plasma. IgG
19  2013 Bioavailability of IgG administered by the subcutaneous route. AUC, SCIG
20  2013 Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. PID, SCIG
21  2013 Human platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model. FNAIT, HPA, i.p, Ig, PBMC, SCID
22  2013 Intravenous immunoglobulin-mediated immunosuppression and the development of an IVIG substitute. IgG
23  2013 [Relationship between the expression of autoantibodies against platelet membrane glycoprotein and therapeutic effect in primary immune thrombocytopenia]. CR, ITP
24  2012 Clinical ambiguities--ongoing questions. PIDD, SCIG
25  2012 Fc-independent phagocytosis: implications for IVIG and other therapies in immune-mediated thrombocytopenia. GP
26  2012 In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. AAV, IgG
27  2012 Overview of routes of IgG administration. IM, s.c, SCIG
28  2011 (124)I-huA33 antibody PET of colorectal cancer. HAI, huA33
29  2011 Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. SCIG
30  2011 Enhanced antibody-dependent cellular phagocytosis by chimeric monoclonal antibodies with tandemly repeated Fc domains. Ab, ADCP, mAbs
31  2011 Human xeno-autoantibodies against a non-human sialic acid serve as novel serum biomarkers and immunotherapeutics in cancer. ---
32  2011 Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin. ---
33  2011 Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. AUC, SCIG, TLRs
34  2010 The other side of immunoglobulin G: suppressor of inflammation. IgG
35  2009 A close look at human IgG sialylation and subclass distribution after lectin fractionation. ---
36  2009 Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients. AMR, IH
37  2009 Autoimmune limbic encephalitis. CSF, LE
38  2009 Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. CIDP
39  2008 Anti-inflammatory actions of intravenous immunoglobulin. IgG
40  2008 Identification of a receptor required for the anti-inflammatory activity of IVIG. CRD
41  2008 The four most common pediatric immunodeficiencies. ---
42  2007 The antiinflammatory activity of IgG: the intravenous IgG paradox. FcgammaR
43  2007 The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. APS, sIVIG
44  2006 Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. ---
45  2005 Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. BP, PF, PV
46  2005 Selective antibody immune deficiency in a patient with Smith-Lemli-Opitz syndrome. ---
47  2004 Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. HRQoL, SCIG, TS
48  2001 Nonspecific human IgG reduces survival in neonatal rats infected with Escherichia coli. ---
49  2001 Restricted VH3 gene usage in phage-displayed Fab that are selected by intravenous immunoglobulin. SLE
50  2000 The covalent interaction of C3 with IgG immune complexes. Abs, Ags, band A, C3b-IC
51  1996 In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. IgSC, PBMC, PWM, SAg
52  1995 Common variable immunodeficiency: clinical aspects and recent progress in identifying the immunological defect(s). CVID
53  1995 Fragmentation of therapeutic human immunoglobulin preparations. Ig, SDS-PAGE, SE-HPLC
54  1993 Effect of various doses of intravenous polyclonal IgG on in vivo levels of 12 pneumococcal antibodies in patients with chronic lymphocytic leukaemia and multiple myeloma. CLL, MM
55  1991 High-dose intravenous IgG treatment and renal function. ---
56  1990 Effects of intravenous immunoglobulin on hemorrhage-induced alterations in plasma cell repertoires. Ig
57  1990 Immunoprophylaxis of infections with respiratory syncytial virus: observations and hypothesis. RSV
58  1989 High-dose IgG treatment for neonatal alloimmune thrombocytopenia. NAT
59  1987 Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and Sindbis viruses) from an intravenous immunoglobulin preparation. fr, PEG, PFU